$ZNTL News

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

Zentalis Pharmaceuticals Presents Data From Its Interim Analysis Of DENALI Part 1b Trial At ESMO Congress 2026

HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating

Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

Zentalis Pharmaceuticals Announces Proposed Public Offering Of Shares And Pre-Funded Warrants

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)